Announcement of the Establishment of the Nucleic Acid Medicine API Development Center
[Announcement of New Base Establishment] Opening of a new GMP manufacturing facility for oligonucleotides.
Ajinomoto Bio-Pharma Services and Gene Design will strengthen its contract development and production system from the early stages of development to late stages and market launch by introducing large-scale production facilities. With the establishment of the new site, the production volume per lot will expand to the kilogram level. By combining our production capacity with the mass production technology of the Ajinomoto Group, a flexible and seamless supply system will be established, transitioning from conventional μg manufacturing to over 100 kg. [Overview] - Newly established within the research facility in Ibaraki City, Osaka Prefecture - Combined with the mass production technology of the Ajinomoto Group (AJIPHASE technology) - Establishing a supply system from conventional μg to over 100 kg *For more details, please refer to the PDF document or feel free to contact us.
- Company：ジーンデザイン
- Price：Other
